{"id":"abp-692","safety":{"commonSideEffects":[{"rate":null,"effect":"Amyloid-related imaging abnormalities (ARIA) - microhemorrhages"},{"rate":null,"effect":"Amyloid-related imaging abnormalities (ARIA) - edema"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3697359","moleculeType":"Small molecule","molecularWeight":"423.42"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"ABP 692 binds to amyloid-beta protofibrils, which are believed to be toxic intermediates in Alzheimer's disease pathogenesis. By targeting these specific conformations of amyloid-beta, the drug aims to reduce neuroinflammation and slow cognitive decline. This mechanism is distinct from other anti-amyloid approaches that target different forms of amyloid-beta aggregates.","oneSentence":"ABP 692 is a monoclonal antibody that targets amyloid-beta protofibrils to reduce amyloid pathology in Alzheimer's disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:43:57.511Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage)"}]},"trialDetails":[{"nctId":"NCT06700343","phase":"PHASE3","title":"Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)","status":"RECRUITING","sponsor":"Amgen","startDate":"2025-01-13","conditions":"Relapsing-remitting Multiple Sclerosis (RRMS)","enrollment":444}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":7,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ABP 692","genericName":"ABP 692","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ABP 692 is a monoclonal antibody that targets amyloid-beta protofibrils to reduce amyloid pathology in Alzheimer's disease. Used for Early symptomatic Alzheimer's disease (mild cognitive impairment or mild dementia stage).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}